Tag: Sun Pharma
Sun Pharma announces US FDA acceptance of sBLA application for ILUMYA...
If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe plaque psoriasis; FDA decision expected by October 29, 2026
AstraZeneca and Sun Pharma partner to help patients living with Hyperkalaemia...
This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India
Sun Pharma’s phase 3 trials of ILUMYA support potential U.S. submission...
Both pivotal studies met their primary endpoint with statistically significant improvements based on ACR20 response rates at Week 24 with tildrakizumab 100 mg (ILUMYA) compared to placebo
Sun Pharma discontinues studies of its drug for psoriasis & atopic...
The Phase 2 atopic dermatitis study of SCD-044 included 250 people and compared three different dosages of SCD-044 with placebo
Sun Pharma completes its acquisition of Checkpoint Therapeutics
As part of the acquisition, Sun Pharma acquires UNLOXCYTTM, the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Sun Pharma and Moebius Medical announce dual publication on their novel...
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles
Sun Pharma features among top 5% of global pharma companies in...
780 companies have qualified for inclusion in The Sustainability Yearbook 2025 globally
Philogen completes patient enrollment of Phase III FIBROSARC trial in soft...
All ongoing Fibromun trials are expected remain on track with their expected timelines
Burkert inaugurates new manufacturing facility in Pune to strengthen its portfolio...
This state-of-the-art facility is a significant addition to Burkert’s global value chain, aimed at meeting the growing demand in the region by producing components and system solutions
Sun Pharma plans to acquire stake in HaystackAnalytics
HaystackAnalytics is engaged in the business of developing genomic analysis software